Five biotechs emerge as prime oncology M&A targets amid strong pipelines and attractive valuations.

Oncology mergers and acquisitions are accelerating as big pharma seeks new therapies and pipeline renewal. Five biotechs—Incyte, Alnylam, Kymera, Arcus, and Sarepta—stand out for their unique platforms, commercial success, and promising clinical pipelines. Incyte leads with strong revenue and cash reserves, while Alnylam offers a transformative RNAi platform with rapid growth. Kymera and Arcus present innovative targeted therapies with upcoming clinical data, and Sarepta offers gene therapy at a deep valuation discount. These companies are attractive for acquisition due to their pipeline depth, novel technologies, and potential for revenue growth, though risks remain around clinical trial outcomes and regulatory approvals.